Standard BioTools to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Standard BioTools Inc. (Nasdaq:LAB) has announced its management team's participation in two upcoming investor conferences in August 2024. The events are:
1. Canaccord Genuity 44th Annual Growth Conference on August 13th, where President and CEO Michael Egholm, PhD, will participate in a fireside chat at 9:00 a.m. ET.
2. UBS Genomic Medicine Summit on August 14th, where Dr. Egholm will join a panel discussion titled 'Expanding Horizons - Spatial and Beyond' at 2:00 p.m. PT.
Available presentations will be webcast live on the company's Investor Relations page. Recordings will be archived and accessible at investors.standardbio.com.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, LAB gained 3.27%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), today announced that its management team will participate in the following investor conferences in the month of August:
- Canaccord Genuity 44th Annual Growth Conference on August 13th, 2024
President and CEO, Michael Egholm, PhD, will participate in a fireside chat on Tuesday, August 13, 2024, at 9:00 a.m. ET - UBS Genomic Medicine Summit on August 14th, 2024
President and CEO, Michael Egholm, PhD, will participate in a panel discussion:
Expanding Horizons - Spatial and Beyond on Wednesday, August 14, 2024, at 2:00 p.m. PT
Available presentations will be webcast live and available on the Investor Relations page of the Company’s website at Events & Presentations. A recording will be archived and available on the Standard BioTools Investor Relations page at investors.standardbio.com.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq:LAB), the parent company of SomaLogic Inc. and previously known as Fluidigm Corporation, has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.
For Research Use Only. Not for use in diagnostic procedures.
Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms. Patent and License Information: standardbio.com/legal/notices.
Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.
Investor Contact:
David Holmes
Gilmartin Group LLC
(332) 330-1031
ir@standardbio.com
FAQ
What investor conferences will Standard BioTools (LAB) participate in during August 2024?
Who will represent Standard BioTools (LAB) at these investor conferences?
What type of presentation will Standard BioTools (LAB) give at the Canaccord Genuity conference?
What panel will Standard BioTools (LAB) participate in at the UBS Genomic Medicine Summit?
Where can investors access the webcasts of Standard BioTools (LAB) presentations?
